Cargando…

Systems-level biomarkers identification and drug repositioning in colorectal cancer

Colorectal cancer (CRC) is the most commonly diagnosed fatal cancer in both women and men worldwide. CRC ranked second in mortality and third in incidence in 2020. It is difficult to diagnose CRC at an early stage as there are no clinical symptoms. Despite advances in molecular biology, only a limit...

Descripción completa

Detalles Bibliográficos
Autores principales: Beklen, Hande, Yildirim, Esra, Kori, Medi, Turanli, Beste, Arga, Kazim Yalcin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299930/
https://www.ncbi.nlm.nih.gov/pubmed/34322194
http://dx.doi.org/10.4251/wjgo.v13.i7.638
_version_ 1783726358202941440
author Beklen, Hande
Yildirim, Esra
Kori, Medi
Turanli, Beste
Arga, Kazim Yalcin
author_facet Beklen, Hande
Yildirim, Esra
Kori, Medi
Turanli, Beste
Arga, Kazim Yalcin
author_sort Beklen, Hande
collection PubMed
description Colorectal cancer (CRC) is the most commonly diagnosed fatal cancer in both women and men worldwide. CRC ranked second in mortality and third in incidence in 2020. It is difficult to diagnose CRC at an early stage as there are no clinical symptoms. Despite advances in molecular biology, only a limited number of biomarkers have been translated into routine clinical practice to predict risk, prognosis and response to treatment. In the last decades, systems biology approaches at the omics level have gained importance. Over the years, several biomarkers for CRC have been discovered in terms of disease diagnosis and prognosis. On the other hand, a few drugs are being developed and used in clinics for the treatment of CRC. However, the development of new drugs is very costly and time-consuming as the research and development takes about 10 years and more than $1 billion. Therefore, drug repositioning (DR) could save time and money by establishing new indications for existing drugs. In this review, we aim to provide an overview of biomarkers for the diagnosis and prognosis of CRC from the systems biology perspective and insights into DR approaches for the prevention or treatment of CRC.
format Online
Article
Text
id pubmed-8299930
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-82999302021-07-27 Systems-level biomarkers identification and drug repositioning in colorectal cancer Beklen, Hande Yildirim, Esra Kori, Medi Turanli, Beste Arga, Kazim Yalcin World J Gastrointest Oncol Review Colorectal cancer (CRC) is the most commonly diagnosed fatal cancer in both women and men worldwide. CRC ranked second in mortality and third in incidence in 2020. It is difficult to diagnose CRC at an early stage as there are no clinical symptoms. Despite advances in molecular biology, only a limited number of biomarkers have been translated into routine clinical practice to predict risk, prognosis and response to treatment. In the last decades, systems biology approaches at the omics level have gained importance. Over the years, several biomarkers for CRC have been discovered in terms of disease diagnosis and prognosis. On the other hand, a few drugs are being developed and used in clinics for the treatment of CRC. However, the development of new drugs is very costly and time-consuming as the research and development takes about 10 years and more than $1 billion. Therefore, drug repositioning (DR) could save time and money by establishing new indications for existing drugs. In this review, we aim to provide an overview of biomarkers for the diagnosis and prognosis of CRC from the systems biology perspective and insights into DR approaches for the prevention or treatment of CRC. Baishideng Publishing Group Inc 2021-07-15 2021-07-15 /pmc/articles/PMC8299930/ /pubmed/34322194 http://dx.doi.org/10.4251/wjgo.v13.i7.638 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Review
Beklen, Hande
Yildirim, Esra
Kori, Medi
Turanli, Beste
Arga, Kazim Yalcin
Systems-level biomarkers identification and drug repositioning in colorectal cancer
title Systems-level biomarkers identification and drug repositioning in colorectal cancer
title_full Systems-level biomarkers identification and drug repositioning in colorectal cancer
title_fullStr Systems-level biomarkers identification and drug repositioning in colorectal cancer
title_full_unstemmed Systems-level biomarkers identification and drug repositioning in colorectal cancer
title_short Systems-level biomarkers identification and drug repositioning in colorectal cancer
title_sort systems-level biomarkers identification and drug repositioning in colorectal cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299930/
https://www.ncbi.nlm.nih.gov/pubmed/34322194
http://dx.doi.org/10.4251/wjgo.v13.i7.638
work_keys_str_mv AT beklenhande systemslevelbiomarkersidentificationanddrugrepositioningincolorectalcancer
AT yildirimesra systemslevelbiomarkersidentificationanddrugrepositioningincolorectalcancer
AT korimedi systemslevelbiomarkersidentificationanddrugrepositioningincolorectalcancer
AT turanlibeste systemslevelbiomarkersidentificationanddrugrepositioningincolorectalcancer
AT argakazimyalcin systemslevelbiomarkersidentificationanddrugrepositioningincolorectalcancer